About Cue Biopharma
Cue Biopharma is a company based in Cambridge (United States) founded in 2015. It operates as a HealthTech. Cue Biopharma has raised $10 million across 4 funding rounds from investors including MDB Capital Holdings. The company has 41 employees. Cue Biopharma offers products and services including Engineered Biologics. Cue Biopharma operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Cambridge, United States
- Employees 41
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website cuebiopharma.com
- Social LinkedIn X
- Legal Name Cue Biopharma
- Annual Revenue$27.47 M (USD)195.75as on Dec 31, 2025
- Net Profit-$26.6 M (USD)34.6as on Dec 31, 2025
- EBITDA-$26.17 M (USD)33.3as on Dec 31, 2025
- Total Equity Funding$10M (USD)
in 4 rounds
- Latest Funding Round$50M (USD), Post-IPO
Jul 2026
- Investors
- Employee Count41
Products & Services of Cue Biopharma
Cue Biopharma offers a comprehensive portfolio of products and services, including Engineered Biologics.
Engineered biologics are designed for immune system activation.
Funding Insights of Cue Biopharma
Cue Biopharma has successfully raised a total of $10M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $50 million completed in July 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $10M
- Total Rounds 4
- Last Round Post-IPO — $50M
- First Round $10M
(Jun 2015)
- Investors Count 1
All 4 funding rounds of Cue Biopharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2026 | $50M | Post-IPO | – | – | – |
| May 2026 | $30M | Post-IPO | – | – | – |
| Nov 2022 | $30M | Post-IPO | – | – | – |
| Jun 2015 | $10M | Seed | – | – |
1 investors in total: 1 institutional.
Investors in Cue Biopharma
Cue Biopharma has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include MDB Capital Holdings.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage tech startups are funded by MDB Capital Holdings. | 1997 | mdb.com | Dallas, United States |
Investor details for Cue Biopharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cue Biopharma
36 people are tracked at Cue Biopharma (11 in leadership, 13 in board & advisors, 12 in team); the tracked headcount is 41.
| Name | Role | Group |
|---|---|---|
Annie Kang | Director Of R&d Operations | Leadership |
Natasha Girgis | Director, Translational Pharmacology | Leadership |
Kerri-Ann Millar | Chief Financial Officer | Leadership |
Dan Passeri | President & CEO | Leadership |
James Murray | Associate Director Toxicology & Pharmacology | Leadership |
Reena Lynam | Sr. Director, Clinical Operations | Leadership |
Jason Condon | Director, Drug Substance Technical Operations | Leadership |
Siddhartha Shrivastava | Senior Vice President, Head Of CMC And Global Technical Operations | Leadership |
Steven Quayle | Senior Vice President And Head Of Research & Translational Medicine | Leadership |
Matteo Levisetti | Chief Medical Officer | Leadership |
Anish Suri | Chief Scientific Officer | Leadership |
Hidde Ploegh | Advisor | Board & advisors |
Pamela D. Garzone | Director | Board & advisors |
Karolina Palucka | Advisor | Board & advisors |
Aaron Fletcher | Director | Board & advisors |
Frank Morich | Chairman, Board of Directors | Board & advisors |
Peter Kiener | Director | Board & advisors |
Abul K. Abbas | Advisor | Board & advisors |
Michael Kalos | Advisor | Board & advisors |
Fred Driscoll | Director | Board & advisors |
16 more people are available in the full profile.
Complete people profiles for Cue Biopharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Cue Biopharma
Cue Biopharma is a publicly listed company on the NASDAQ with ticker symbol CUE in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date02 Jan 2018
- Listed onNASDAQ: CUE
- Listed entityCue Biopharma, Inc.
- Exchange sectorHealth technology
Timeline of Cue Biopharma
4 dated milestones of Cue Biopharma across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Cue Biopharma is founded.
- Funding First funding round of $10.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $50.0M.
Competitors of Cue Biopharma
Cue Biopharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| adacap.com | 2002 | Saint Genis Pouilly, France | $56.13M | – | Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. |
Detailed competitors of Cue Biopharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Cue Biopharma
The website of Cue Biopharma (cuebiopharma.com) receives about 4.9K visits a month and ranks #7,063,180 among all websites worldwide, #6,885 in Biotechnology and Pharmaceuticals.
- Monthly visits4.9K
▲ 114.2% vs previous month
- Global rank#7,063,180
among all websites
- Category rank#6,885
Health · Biotechnology and Pharmaceuticals
- Bounce rate38%
- Pages per visit1.7
- Average visit30 sec
- DevicesDesktop 26% · Mobile 74%
Websites whose visitors overlap most with Cue Biopharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| sherlock.bio | 100% | 2.8K | #4,929,420 | View details | |
| ornatx.com | 98% | 4.4K | #3,250,511 | View details | |
| lyndra.com | 97% | – | #9,629,878 | View details | |
| dynotx.com | 96% | 14.4K | #2,089,404 | View details | |
| compasstherapeutics.com | 95% | 8.7K | #3,518,435 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 22 similar websites and full traffic analytics for Cue Biopharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 22 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Cue Biopharma
Complete news archive for Cue Biopharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Cue Biopharma
10 companies that operate in the same segment as Cue Biopharma (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 300 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 194 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Developer of CAAR T cells for B cell-mediated autoimmune diseases | 2017 | Radnor, Pennsylvania, United States | USD 88.26 M | – | 161 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Cue Biopharma
Cue Biopharma was founded in 2015.
Cue Biopharma is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Cue Biopharma is a funded company, having raised a total of $10M across 4 funding rounds to date. The company's 1st funding round was a Seed of $10M, raised on Jun 2015.
Cue Biopharma has 41 employees.
Annual revenue of Cue Biopharma is $27.47M as on Dec 31, 2025.
Cue Biopharma is engaged in the development of engineered biologics aimed at mobilizing the patients immune system to treat serious diseases. The companys solutions are designed to selectively expand and activate specific immune cells while restoring immune balance. Their work primarily targets autoimmune and inflammatory diseases through innovative approaches in the biotechnology sector, with partnerships such as with Boehringer Ingelheim to advance next-generation treatments.
Cue Biopharma's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Cue Biopharma offers Engineered Biologics.
Yes, Cue Biopharma is publicly traded on NASDAQ under the ticker symbol CUE.
Cue Biopharma has 1 investor. Key investors include MDB Capital Holdings.
Cue Biopharma operates through Cue Biopharma.